Compare CISO & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CISO | PLUR |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.8M |
| IPO Year | 2021 | 2026 |
| Metric | CISO | PLUR |
|---|---|---|
| Price | $0.17 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 176.5K | 12.2K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.31 | 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,016,000.00 |
| Revenue This Year | N/A | $902.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $0.85 |
| 52 Week High | $1.31 | $4.87 |
| Indicator | CISO | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 33.03 |
| Support Level | N/A | $0.90 |
| Resistance Level | $0.26 | $1.85 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 28.01 | 36.29 |
CISO Global Inc provides cybersecurity compliance and is a software firm composed of trained and seasoned security professionals. The services are used to protect clients' data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in the U.S., Chile, and all other countries. The maximum revenue is generated from the U.S. The products and services include: security managed services, professional services, and cybersecurity software.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.